Best Primary Care Practices for Hepatitis B Infection: Focus on Screening and Diagnosis

CMEO Chart Review

Premiere Date: Thursday, December 6, 2012



This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. Family Physicians (AAFP)
  5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Wednesday, January 22, 2014


Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF 
Director, Liver Care Network and Organ Care Research
Swedish Medical Center
Seattle, WA

Su Wang, MD, MPH Su Wang, MD, MPH 
Assistant Director of Medical Affairs
Charles B. Wang Community Health Center
Clinical Instructor
Department of Medicine
New York University School of Medicine
New York, NY

Statement of Need

According to the report issued by the Institute of Medicine entitled Hepatitis and Liver Cancer: Information for Health Care Providers, chronic infection with hepatitis B virus (HBV) constitutes a public health problem—one that primary care clinicians can play a critical role in addressing. Specifically, the report calls frontline clinicians to increase screening of at-risk adults, provide better patient education about HBV serologic results, and strengthen efforts toward patient access to treatment and monitoring services either in primary care or via timely referral to specialist care.

This CME Outfitters Chart Review features national experts as your guides on a patient case expedition that will cover the terrain of current national guidelines (from the American Association for the Study of Liver Diseases), emerging data, and expert experience.

This Chart Review focuses on primary care-based screening, diagnosis, and prevention counseling and follows a Live and On Demand activity, the flagship educational experience in the CME Outfitters vWorld™ virtual learning environment.

  • Colvin HM, Mitchell AE, eds.; Institute of Medicine Committee on the Prevention and Control of Viral Hepatitis Infections, Board on Population Health and Public Health Practice. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington DC: National Academies Press; 2011. Accessed October 15, 2012.
  • Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-662. PMID: 19714720.

Additional Education on Hepatitis B: Join the faculty for an additional opportunity to continue the interaction and to discuss clinical case challenges you see in your practice.

Best Primary Care Practices for Hepatitis B Infection: Focus on Therapeutic Strategy Planning and Treatment Counseling
December 20, 2012 at 12:00-1:00 PM ET with Dr. Culpepper and Dr. Tran.
For information and to register Click Here

Activity Goal

To educate primary care clinicians, in accordance with guidelines, on using effective screening, diagnostics, patient education, and general management strategies for adults who have or who are at risk of developing chronic viral hepatitis due to hepatitis B virus infection.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Increase the rate at which at-risk patients are screened for viral hepatitis B infection.
  • Counsel patients who undergo serologic testing for hepatitis B virus on the meaning of their test results.

The following learning objectives pertain only to those requesting CNE credit:

  • Identify at-risk patients who should be screened for hepatitis B infection, in accordance with AASLD guidelines.
  • Correlate serologic patterns with stage of hepatitis B disease and need for treatment in HBsAg-positive patients.

Financial Support

Supported by educational grants from Bristol-Myers Squibb and Gilead Sciences, Inc.

Target Audience

Physicians, physician assistants, nurses, nurse practitioners, pharmacists, and other health care professionals whose scope of practice involves providing primary care for adults who have or who are at risk of developing chronic viral hepatitis.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Credit (Family Physicians):
This enduring material activity, Best Primary Care Practices for Hepatitis B Infection: Focus on Screening and Diagnosis, has been reviewed and is acceptable for up to 1 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins December 6, 2012. Term of approval is for one year from this date with the option of yearly renewal. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.0 contact hour.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.10 CEUs)
Universal Activity Number:
Activity Type: knowledge-based

Post-tests, credit request forms, and activity evaluations must be completed online at (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kowdley has disclosed that he has received research grants from Abbott Laboratories; Beckman Coulter, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Conatus Pharmaceuticals, Inc.; Gilead; Ikaria, Inc.; Intercept Pharmacueticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mochida Pharmaceuticals, Inc.; Vertex Pharmaceuticals Incorporated. He serves as a consultant to/is on the advisory boards of Abbott Laboratories; Gilead; Merck & Co., Inc.; Novartis Corporation and Vertex Pharmaceuticals Incorporated.

Dr. Wang has disclosed that she serves as a consultant to Gilead Sciences, Inc.

Jeffrey Helfand, DO, MS (content/peer reviewer) has no disclosures to report.

Ruth Cody, BSN, RN-BC (content/peer reviewer) has no disclosures to report.

Nancy Jennings, MSN, MBA, MHA, RNC (content/peer reviewer) has no disclosures to report.

Monique Johnson, MD, CCMEP (planning committee) has no disclosures to report.

Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.

Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Unlabeled Use Disclosure

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, Bristol-Myers Squibb, and Gilead Sciences, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

This document was last modified on: